Physician profile
Jenson Abraham
NPI 1205074135
$1,949.97
in general payments reported to CMS, 2019-2025
30 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $77.47 · 2021: $244 · 2022: $255 · 2023: $335 · 2024: $392 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $262.88 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $244.28 | 2019-2025 | Xarelto, Spravato |
| Lilly USA, LLC | $130.48 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Medtronic, INC. | $127.73 | 2021-2025 | Kyphon Express II Kyphopak Tray, Osteocool Rf Ablation System |
| Novartis Pharmaceuticals Corporation | $127.18 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.40 | 2019-2021 | |
| Gilead Sciences, INC. | $93.49 | 2021-2023 | Veklury |
| Inari Medical, INC. | $72.65 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $71.39 | 2024-2025 | |
| Mylan Specialty L.P. | $68.62 | 2019 | |
| Glaxosmithkline, LLC. | $67.69 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $63.62 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $55.65 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.18 | 2021-2024 | Eliquis |
| Corcept Therapeutics | $47.81 | 2025 | Korlym |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44.13 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.04 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $34.50 | 2025 | Veozah |
| Lundbeck LLC | $32.07 | 2025 | Rexulti |
| Amgen INC. | $26.50 | 2024 | Otezla, Repatha |
| Fisher & Paykel Healthcare INC | $24.79 | 2022 | |
| Dexcom, INC. | $22.92 | 2025 | Dexcom G6 Transmitter |
| Heron Therapeutics, INC. | $22.82 | 2025 | Zynrelef |
| Alvogen INC | $20.09 | 2025 | Teriparatide |
| Exact Sciences Corporation | $19.21 | 2024 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $17.43 | 2025 | |
| Novo Nordisk INC | $14.53 | 2024 | Wegovy |
| Antares Pharma, INC. | $13.47 | 2025 | Xyosted |
| Phathom Pharmaceuticals, INC. | $13.23 | 2025 | Voquezna |
| Medtronic Vascular, INC. | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenson Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.